SELLAS Life Sciences Group, Inc.
SLSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, SELLAS Life Sciences Group, Inc. (SLS) is listed under Biotechnology. With a market capitalization of $2.33B, it sits in mid-cap territory. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Cap
$2.33B
Beta
2.57
P/E (TTM)
—
P/E (Fwd)
-115.40
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.10
ROE
-39.6%
ROA
-23.3%
Cash
$138.3M
Total Debt
$737,000
Free CF
-$16.4M
52W Change
479.9%
Annual Financials
Cash vs Debt
Where SLS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SLS finished 9.96% above its 150-day moving average ($9.54) and 27.15% above its 200-day moving average ($8.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLS overbought or oversold?
At the October 20, 2026 close, SLS's RSI(14) was 42.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $138.3M in cash and $737K in debt, SLS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$16.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.0M (2022) to $0 (2025), a 100% decline worth watching.
SELLAS Life Sciences Group, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SELLAS Life Sciences Group, Inc. and its sector.